JP2007516202A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516202A5
JP2007516202A5 JP2006518353A JP2006518353A JP2007516202A5 JP 2007516202 A5 JP2007516202 A5 JP 2007516202A5 JP 2006518353 A JP2006518353 A JP 2006518353A JP 2006518353 A JP2006518353 A JP 2006518353A JP 2007516202 A5 JP2007516202 A5 JP 2007516202A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006518353A
Other languages
English (en)
Japanese (ja)
Other versions
JP4653741B2 (ja
JP2007516202A (ja
Filing date
Publication date
Priority claimed from GBGB0315966.2A external-priority patent/GB0315966D0/en
Application filed filed Critical
Publication of JP2007516202A publication Critical patent/JP2007516202A/ja
Publication of JP2007516202A5 publication Critical patent/JP2007516202A5/ja
Application granted granted Critical
Publication of JP4653741B2 publication Critical patent/JP4653741B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006518353A 2003-07-08 2004-07-07 プロテインキナーゼ阻害能のあるチアゾロ−、オキサゾロ−、及びイミダゾロ−キナゾリン化合物 Expired - Fee Related JP4653741B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315966.2A GB0315966D0 (en) 2003-07-08 2003-07-08 Compounds
PCT/GB2004/002935 WO2005005438A1 (en) 2003-07-08 2004-07-07 Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases

Publications (3)

Publication Number Publication Date
JP2007516202A JP2007516202A (ja) 2007-06-21
JP2007516202A5 true JP2007516202A5 (enExample) 2011-01-13
JP4653741B2 JP4653741B2 (ja) 2011-03-16

Family

ID=27741793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006518353A Expired - Fee Related JP4653741B2 (ja) 2003-07-08 2004-07-07 プロテインキナーゼ阻害能のあるチアゾロ−、オキサゾロ−、及びイミダゾロ−キナゾリン化合物

Country Status (12)

Country Link
US (1) US7576091B2 (enExample)
EP (1) EP1641805B1 (enExample)
JP (1) JP4653741B2 (enExample)
CN (1) CN100404540C (enExample)
AT (1) ATE455119T1 (enExample)
AU (1) AU2004255924B8 (enExample)
BR (1) BRPI0412363A (enExample)
CA (1) CA2530455A1 (enExample)
DE (1) DE602004025112D1 (enExample)
GB (1) GB0315966D0 (enExample)
IL (1) IL172993A0 (enExample)
WO (1) WO2005005438A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
RU2403258C2 (ru) 2004-10-07 2010-11-10 Бёрингер Ингельхайм Интернациональ Гмбх Тиазолилдигидроиндазолы
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
DE102005048072A1 (de) * 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102006001161A1 (de) * 2006-01-06 2007-07-12 Qiagen Gmbh Verfahren zum Nachweis von Cytosin-Methylierungen
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
TW200808805A (en) * 2006-04-12 2008-02-16 Vertex Pharma Tetrahydropteridines useful as inhibitors of protein kinases
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
WO2009047359A1 (en) 2007-10-12 2009-04-16 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
WO2010043676A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2432671T3 (es) 2009-07-02 2013-12-04 Novartis Ag 2-carboxamida cicloamino ureas útiles como inhibidores de PI3K
US8518948B2 (en) 2010-03-10 2013-08-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US20170283445A1 (en) 2016-04-05 2017-10-05 University Of South Carolina Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
CN114213421A (zh) * 2017-04-01 2022-03-22 晟科药业(江苏)有限公司 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
JP7233743B2 (ja) * 2017-08-11 2023-03-07 晟科薬業(江蘇)有限公司 プロテインキナーゼ阻害剤としての1h-ピラゾロ[4,3-h]キナゾリン系化合物
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3992196B1 (en) * 2019-08-02 2023-12-13 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. 1h-[1, 2, 3]triazolo[4, 5-h] quinazoline compounds acting as protein kinase inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
EP4204093A1 (en) * 2020-08-27 2023-07-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors
US12559733B2 (en) 2020-10-22 2026-02-24 University Of South Carolina Optimization of type IV BRAF inhibitors for the treatment of melanoma
WO2022111634A1 (zh) * 2020-11-26 2022-06-02 成都赛璟生物医药科技有限公司 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂
EP4284371A4 (en) * 2021-01-29 2024-12-18 Virokyne Therapeutics, Llc SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS FOR THE THERAPEUTIC USE THEREOF
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN121368595A (zh) * 2023-06-01 2026-01-20 成都赛璟生物医药科技有限公司 1h-[1,2,3]三唑并[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2001242629B2 (en) * 2000-03-29 2005-08-11 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1345925B1 (en) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2005261231A5 (enExample)
JP2007514712A5 (enExample)
JP2008512492A5 (enExample)
JP2005194118A5 (enExample)
JP2004244619A5 (enExample)
JP2006257115A5 (enExample)
JP2008512356A5 (enExample)
JP2004168997A5 (enExample)
JP2008512398A5 (enExample)
JP2007505861A5 (enExample)
JP2003305787A5 (enExample)
JP2005120465A5 (enExample)
JP2006063441A5 (enExample)
JP2007119645A5 (enExample)
JP2005095148A5 (enExample)
JP2006045672A5 (enExample)
JP2005290409A5 (enExample)
JP2006101735A5 (enExample)
JP2006523255A5 (enExample)
JP2008525570A5 (enExample)
JP2007525546A5 (enExample)
JP2007526266A5 (enExample)
JP2006273834A5 (enExample)
JP2008524415A5 (enExample)
JP2008525527A5 (enExample)